Physician profile
Molly Shotts
NPI 1376103895
$2,585.27
in general payments reported to CMS, 2019-2025
16 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,502 · 2022: $487 · 2023: $547 · 2024: $50.25.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $597.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $596.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $1,055.88 | 2021-2024 | Senza |
| Boston Scientific Corporation | $437.45 | 2021-2023 | |
| Abbvie INC. | $315.65 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $253.20 | 2021 | |
| Medtronic, INC. | $165.98 | 2021 | |
| Collegium Pharmaceutical, INC. | $88.92 | 2021 | |
| Redhill Biopharma INC. | $47.74 | 2021 | |
| Allergan, INC. | $44.49 | 2021 | |
| Horizon Therapeutics Plc | $42.89 | 2021 | |
| Novartis Pharmaceuticals Corporation | $31.48 | 2021 | |
| Arbor Pharmaceuticals, INC. | $19.17 | 2021 | |
| Upsher-Smith Laboratories LLC | $18.06 | 2021 | |
| Almatica Pharma LLC | $16.89 | 2021 | |
| Pacira Therapeutics, INC. | $16.78 | 2021 | |
| Ibsa Pharma INC. | $16.25 | 2021 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $14.44 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Shotts listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.